無料プレビュー

Karuna Therapeutics, Inc. (KRTX) · NASDAQ Global Market

プロフィール

Operating as a clinical-stage biopharmaceutical firm, Karuna Therapeutics, Inc. is dedicated to pioneering innovative therapies for individuals afflicted by psychiatric and neurological disorders. Its primary investigational compound, KarXT, is an oral agent designed to modulate muscarinic receptors. Currently in Phase III clinical trials, KarXT is being evaluated for several indications: the treatment of acute psychosis in schizophrenia patients, the amelioration of central nervous system conditions (including the negative and cognitive symptoms associated with schizophrenia and general psych

主要指標

株価: $329.83 (+0.03%)
時価総額: 126億ドル
PER（今期予想）: -28.6
PBR: 9.7
配当利回り: —
52週レンジ: $158.38 – $329.99
業種: Healthcare / Biotechnology
上場: NASDAQ Global Market
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、BDX Becton, Dickinson and Company、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

更新: 2026-10-09